Release of Olink® Analyze 3.1 streamlines proteomic analysis to connect data to biological insight

  • Read time: 3 minutes

Press release: Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that it has entered into an agreement with Discovery Life Sciences™ (Discovery) to establish the largest commercial platform of the Olink® technology in the Americas outside of Olink, and provide the market with a global “one-stop shop” to support the discovery and validation of proteomics at scale and with high specificity across all major biological pathways and sample matrices.

“Protein biomarker discovery can help bridge the gap between genomes and phenotypes, enabling improved understanding of real-time human biology and a stronger grasp of the transition from health to disease. With its high specificity, precision, and sensitivity, at scale, Olink’s PEA technology addresses limitations that historically impeded advanced proteomics,” said Jon Heimer, CEO of Olink. “We are excited to support Discovery Life Sciences on their mission to embrace the promise of proteomics through our innovative and unique technology and help leverage its potential for their customers worldwide.”

Olink’s agreement with Discovery, which includes Olink® Explore and the Signature Q100 instrument, represents the latest addition to the rapidly growing community of service providers. This group is collectively embracing Olink’s proteomics platform, from high-plex to low-plex and across major geographies around the world, further growing the proteomics market and increasing Olink’s reach with new customers.

“Olink’s PEA technology is a unique antibody-based proteomic technology with features that solve the dynamic range issue that has hindered proteomics: allowing the detection and quantitation of low and high abundant proteins,” said Michael Pisano, Ph.D., Executive Vice President of Proteomics at Discovery. “Discovery is excited to add this significant installation of the Olink® technology to our extensive menu of proteomic services and optimized workflows that accelerate precision medicine programs through every stage of development, at any scale.”

Discovery will offer Olink® PEA technology to complement their genomic, cell biology, and tissue biomarker services, providing multi-omic analyses that inform and accelerate decision-making throughout drug and diagnostic development.

Investor Contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com

Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: +46 768 775 275
andrea.prander@olink.com

About Olink

Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

2947

Biomarker assays

~881 million

Protein data points generated

997

Publications listed on website

Contact us!